English
French
German
Italian
Russian
Spanish
4 big analyst cuts: Citizens Financial slashed on capital, profitability concerns
4 big analyst cuts: Citizens Financial slashed on capital, profitability concerns By Investing.com
Breaking News
‘;
Published Jun 30, 2023 06:04AM ET
(C) Reuters.
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Citizens Financial, Core Laboratories, Concentrix, and Sonder.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
Citizens Financial slashed to Neutral at JPMorgan
JPMorgan downgraded Citizens Financial (NYSE:CFG) to Neutral from Overweight and cut its price target to $27.00 from $29.00, citing concerns about the bank’s capital requirements and profitability levels.
The recent 2023 DFAST results showed that all banks in JPMorgan’s coverage had capital in excess of minimum requirements, but Citizens is expected to face increased capital requirements, leading to pressure on profitability.
According to the firm, Citizens has a lower cushion relative to peers above minimum CET1 requirements based on 3/31 levels and has continued to buy back stock in Q2. The bank also faces challenges from high losses on commercial real estate (CRE) loans due to the high level of maturities of office CRE loans in 2023 and 2024.
Core Laboratories downgraded to Sell at Citi
Core Laboratories (NYSE:CLB) shares fell more than 1% pre-market today after Citi downgraded the company to Sell from Neutral and cut its price target to $21.00 from $22.00, as reported in real time on InvestingPro.
The bank cut its Q2/23 EBITDA forecast by approximately 5% to $18.9 million, around 6% below the Street estimate, on NAM completion weakness negatively impacting Production Enhancement.
Shares are up approximately 20% YTD and have outperformed its SMID OFS peers materially, but Citi believes this run likely ends soon given negative revisions.
2 more downgrades
BofA Securities downgraded Concentrix (NASDAQ:CNXC) to Neutral from Buy and cut its price target to $95.00 from $165.00. The company reported its Q2 results earlier this week, with EPS and revenues coming in worse than the consensus estimates.
JMP Securities downgraded Sonder (NASDAQ:SOND) to Market Perform from Market Outperform.
Get ready to supercharge your investment strategy with our exclusive discounts.
Don’t miss out on this limited-time opportunity to access cutting-edge tools, real-time market analysis, and expert insights. Join InvestingPro today and unlock your investing potential. Hurry, the Summer Sale won’t last forever!
4 big analyst cuts: Citizens Financial slashed on capital, profitability concerns
Related Articles
Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information
(C) 2007-2023 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
